Akebia Therapeutics Inc (AKBA)
1.82
+0.03
(+1.68%)
USD |
NASDAQ |
Nov 21, 16:00
1.81
-0.01
(-0.55%)
After-Hours: 20:00
Akebia Therapeutics Enterprise Value: 401.43M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 401.43M |
| November 20, 2024 | 394.88M |
| November 19, 2024 | 401.43M |
| November 18, 2024 | 397.06M |
| November 15, 2024 | 394.88M |
| November 14, 2024 | 410.15M |
| November 13, 2024 | 423.24M |
| November 12, 2024 | 429.79M |
| November 11, 2024 | 438.52M |
| November 08, 2024 | 427.61M |
| November 07, 2024 | 411.24M |
| November 06, 2024 | 440.70M |
| November 05, 2024 | 410.15M |
| November 04, 2024 | 407.97M |
| November 01, 2024 | 361.84M |
| October 31, 2024 | 355.50M |
| October 30, 2024 | 363.96M |
| October 29, 2024 | 366.07M |
| October 28, 2024 | 349.15M |
| October 25, 2024 | 340.69M |
| October 24, 2024 | 338.57M |
| October 23, 2024 | 340.69M |
| October 22, 2024 | 351.26M |
| October 21, 2024 | 294.15M |
| October 18, 2024 | 287.80M |
| Date | Value |
|---|---|
| October 17, 2024 | 285.69M |
| October 16, 2024 | 285.69M |
| October 15, 2024 | 281.46M |
| October 14, 2024 | 283.57M |
| October 11, 2024 | 283.57M |
| October 10, 2024 | 275.11M |
| October 09, 2024 | 275.11M |
| October 08, 2024 | 283.57M |
| October 07, 2024 | 283.57M |
| October 04, 2024 | 285.69M |
| October 03, 2024 | 283.57M |
| October 02, 2024 | 287.80M |
| October 01, 2024 | 275.11M |
| September 30, 2024 | 283.57M |
| September 27, 2024 | 278.22M |
| September 26, 2024 | 278.22M |
| September 25, 2024 | 276.11M |
| September 24, 2024 | 282.42M |
| September 23, 2024 | 274.01M |
| September 20, 2024 | 286.63M |
| September 19, 2024 | 286.63M |
| September 18, 2024 | 282.42M |
| September 17, 2024 | 286.63M |
| September 16, 2024 | 292.94M |
| September 13, 2024 | 305.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-32.82M
Minimum
Nov 29 2022
1.776B
Maximum
Jun 29 2020
365.61M
Average
279.52M
Median
Apr 15 2024
Enterprise Value Benchmarks
| Corcept Therapeutics Inc | 5.479B |
| Eli Lilly and Co | 739.59B |
| Bioventus Inc | 1.131B |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.04M |
| Revenue (Quarterly) | 37.43M |
| Total Expenses (Quarterly) | 49.93M |
| EPS Diluted (Quarterly) | -0.10 |
| Gross Profit Margin (Quarterly) | 62.16% |
| Profit Margin (Quarterly) | -53.54% |
| Earnings Yield | -12.46% |
| Normalized Earnings Yield | -12.66 |